Radiofrequency Ablation for Barrett’s Esophagus

Last Review Date: May 12, 2017

Number: MG.MM.ME.42aC

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Barrett’s Esophagus and Dysplasia — Barrett’s esophagus (BE) is defined as a pre-malignant lesion where the normal squamous epithelium that lines the esophagus is replaced by columnar epithelium similar to that in the lining of the intestines. It is detected in the majority of patients with esophageal and gastroesophageal adenocarcinomas.

HALO Systems (BÂRRX Medical, Inc.) — FDA-approved radiofrequency ablation (RFA) treatment system that utilizes heat to destroy BE tissue lining the inside of the esophagus. RFA is an alternative to esophagectomy or endomucosal resection for high or low-grade esophageal dysplasia.

1. HALO\(^{360}\) System — the HALO\(^{360}\) Ablation Catheter is used to introduce a heated balloon that provides a circumferential (360 degree 3 cm long) ablation of circumferential segments ≥ 3cm long. If the heater element is not long enough to cover all of the BE tissue present, the procedure can be repeated at different sites along the esophagus.

2. HALO\(^{90}\) System — introduced endoscopically, the HALO\(^{90}\) Ablation Catheter is used for the primary treatment of smaller areas (e.g., islands and tongues) or as a secondary treatment after circumferential ablation or other therapeutic devices.

Patients typically undergo BÂRRX therapy as outpatients using conscious sedation. This therapy is administered by a trained gastroenterologist.
Guideline
Members are eligible for RFA coverage for BE dysplasia as follows:

1. High-grade:
   a. Confirmed by endoscopy
   b. Life expectancy $\geq$ 1 year

2. Low-grade:
   a. Confirmed by 2 pathologists

Limitations/Exclusions

1. Repeat RFA may be medically necessary for recurrent high-grade dysplasia.
2. RFA is not considered medically necessary for nondysplastic BE, as it has not been shown to improve health outcomes when coupled with endoscopic surveillance.
3. Coverage is limited to FDA-approved devices.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>43229</td>
<td>Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)</td>
</tr>
<tr>
<td>43270</td>
<td>Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>K22.710</td>
<td>Barrett's esophagus with low grade dysplasia</td>
</tr>
<tr>
<td>K22.711</td>
<td>Barrett's esophagus with high grade dysplasia</td>
</tr>
</tbody>
</table>

References